Analysts Peeling Back the Layers on Intersect ENT, Inc. (NASDAQ:XENT)

Intersect ENT, Inc. (NASDAQ:XENT) currently has an Average Broker Rating of 1.4. The ABR rank within the industry stands at 21. This number is based on the 10 sell-side firms polled by Zacks.  

Successfully tackling the equity markets may involve owning a wide range of stocks. Some investors may prefer growth stocks while others may opt for value stocks. Having a good mix of both types may help build of solid foundation for the portfolio. Investors may choose stocks in a specific industry that is gaining strength. If the industry is on the rise, the portfolio may be more likely to succeed. Finding companies that are considered leaders in their field may also be on the investor checklist. A company that has a large presence may help ease investor worry, especially in a down market climate. Finding the perfect stocks to add to the portfolio may not always be easy, and in fact it may be quite difficult. Investors may have to lay out goals to help keep things on track for both the short-term and the long haul.

Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR. 

As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.

Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.

For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.

Analysts on a consensus basis are expecting that the stock will reach $31.67 within the year.

Investors may be combing through all the latest earnings reports and trying to make sense of all the numbers. With lots of information readily available, investors may be searching for that next batch of stocks to add to the portfolio. Finding high quality stocks may be at the top of the investor’s checklist. Once high quality stocks are spotted, the investor may be then looking for bargains among those stocks. Many investors will look for stocks that have displayed consistent earnings growth over an extended period of time. When a company drastically over performs for a quarter, investors may be quick to investigate. The same things may be done if a company severely underperforms compared to projections. 

Most recently Intersect ENT, Inc. (NASDAQ:XENT) posted quarterly earnings of $-0.08 which compared to the sell-side estimates of -0.19. The stock’s 12-month trailing earnings per share stands at $-0.7. Shares have moved $-0.33 over the past month and more recently, $-4.4 over the past week heading into the earnings announcement. There are 8 analyst projections that were taken into consideration from respected brokerage firms.

Research analysts are predicting that Intersect ENT, Inc. (NASDAQ:XENT) will report earnings of $-0.2 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Intersect ENT, Inc. (NASDAQ:XENT) closed the last session at $30.4 and sees an average of 194265.34 shares trade hands in each session. The 52-week low of the stock stands at $8.35 while the current level stands at 90.18% of the 52-week High-Low range. Looking further out we can see that the stock has moved 12.18% over the past 12 weeks and 151.24% year to date.

8 analysts rate Intersect ENT, Inc. a Buy or Strong Buy, which is 80% of all the analyst ratings.

Leave a Comment